Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMalignant neoplasms of mesothelial and soft tissueICD-10-CM c48-malignant-neoplasm-retroperitoneum-peritoneum
    Ask Trek AI about this page

    ICD-10-CM Code For Malignant Neoplasm Of Retroperitoneum And Peritoneum: Group Overview

    The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code group C48 includes malignant neoplasms arising in the retroperitoneum and peritoneum, covering primary soft tissue sarcomas, mesotheliomas of peritoneal surfaces, and other malignant tumors of these anatomical spaces. These ICD-10-CM diagnosis codes are used to document clinical scenarios such as primary retroperitoneal sarcoma, peritoneal carcinomatosis when specified as primary peritoneal malignancy, and mesothelial malignancies, capturing tumor location, extent, and involvement of adjacent structures. Accurate coding within the ICD-10-CM C48 group supports proper claim adjudication, complete clinical documentation, and appropriate reimbursement.

    Customize your policy alerts

    Sign up for ICD-10-CM Code For Malignant Neoplasm Of Retroperitoneum And Peritoneum: Group Overview policy alerts

    Get alerted when relevant policies change without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    ICD-10-CM C48: Malignant Neoplasm Of Retroperitoneum And Peritoneum Overview

    The ICD-10-CM C48 group represents malignant tumors originating in the retroperitoneal space and peritoneal surfaces, including soft tissue and mesothelial neoplasms. These diagnoses affect abdominal and pelvic compartments and can involve adjacent organs and structures. Accurate coding is important for complete clinical documentation and can impact reimbursement and claim adjudication.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    When to Use

    Use a code from this group when a clinician documents a primary malignant neoplasm arising in the retroperitoneum or peritoneum as the site of origin. Select the most specific code available that reflects the location and laterality if applicable, and include additional codes for metastatic disease or complications when documented.

    ICD-10-CM Codes

    4 rows

    ICD-10-CM CodeDescription
    C48.0Malignant neoplasm of retroperitoneum
    C48.1Malignant neoplasm of specified parts of peritoneum
    C48.2Malignant neoplasm of peritoneum, unspecified
    C48.8Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum

    DRG Codes

    11 rows

    DRG CodeDescription
    374Digestive Malignancy with MCC
    375Digestive Malignancy with CC
    376Digestive Malignancy without CC/MCC
    826Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC
    827Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC
    828Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC
    829Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC
    830Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC
    843Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC
    844Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with CC
    845Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses without CC/MCC

    Typical Clinical Scenarios

    • An elderly patient presents to the emergency department with progressive abdominal distension, early satiety, and increasing abdominal pain over several weeks. Imaging (CT abdomen/pelvis) reveals a large, lobulated mass occupying the peritoneal cavity with omental caking and ascites; biopsy confirms a malignant soft-tissue neoplasm arising from the peritoneal lining. A code from this group is assigned to capture a primary malignant neoplasm of the peritoneum. Typical codes: C48.1, C48.8
    • A middle-aged patient with a history of vague, chronic flank discomfort and unintended weight loss is evaluated in clinic; MRI identifies a retroperitoneal mass encasing the psoas muscle without visceral organ origin. Core needle biopsy demonstrates a high-grade sarcomatous malignancy of retroperitoneal soft tissue, and the diagnosis is recorded for staging and treatment planning. Typical codes: C48.0, C48.2
    • A patient undergoing follow-up after cytoreductive surgery for a previously treated peritoneal malignancy now presents with bowel obstruction symptoms; operative findings show recurrent tumor deposits along the parietal peritoneum causing adhesive obstruction. The encounter documents the malignant recurrence in the peritoneal surfaces as a comorbid condition impacting management. Typical codes: C48.1, C48.8}

    Related Codes

    C45-MESOTHELIOMA

    ICD-10-CM Code For Mesothelioma: Group Overview

    C46-KAPOSIS-SARCOMA

    ICD-10-CM Code For Kaposi's Sarcoma: Group Overview

    C47-MALIGNANT-NEOPLASM-PERIPHERAL-NERVES

    ICD-10-CM Code For Malignant Neoplasm Of Peripheral Nerves And Autonomic Nervous System: Group Overview

    C49-MALIGNANT-NEOPLASM-OF-SOFT-TISSUE

    ICD-10-CM Code For Malignant Neoplasm Of Other Connective And Soft Tissue: Group Overview

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.